Seonix Bio Announces US Launch of SightScore, the First Commercially Available Clinical Polygenic Risk Score Testing Service for Glaucoma

SAN DIEGO--(BUSINESS WIRE)--Seonix Bio, a leader in the development of genetic testing for glaucoma, today announced the U.S. launch of SightScore, the first commercially available clinical polygenic risk score testing service for primary open-angle glaucoma. SightScore uses a saliva test to identify individuals at high risk for glaucoma, enabling earlier diagnosis, intervention, and more personalized treatment while also identifying low-risk individuals who may benefit from less frequent monit